This bill amends the Patient Protection and Affordable Care Act to add fertility treatment and care as an essential health benefit. It defines the scope of fertility services, including preservation of reproductive material, artificial insemination, assisted reproductive technology (ART) such as IVF, genetic testing of embryos, medications, gamete donation, and related services, aligned with professional guidelines.
It also imposes parity in cost sharing and treatment limitations for fertility benefits, prohibits denial of coverage based on infertility, and requires data collection on utilization-management practices with federal oversight. The amendments target plans offered in the individual and small group markets and become effective for plan years beginning one year after enactment.
At a Glance
What It Does
Amends ACA 1302(b) to add fertility treatment and care as an essential health benefit, with a detailed definition of covered services and related requirements.
Who It Affects
Health insurance issuers in the individual and small group markets, and individuals seeking fertility treatment and care.
Why It Matters
Creates parity with other medical benefits, reduces coverage gaps for infertility, and introduces monitoring to align utilization practices with clinical guidelines.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Health Coverage for IVF Act of 2025 expands the list of benefits that must be covered by certain ACA plans by adding fertility treatment and care. It defines what counts as fertility treatment (from preserving eggs and sperm to IVF and related procedures, along with genetic testing and medications) and directs the Secretary to allow additional related services as appropriate.
Importantly, the bill requires that fertility benefits not be more restricted than the typical medical benefits covered by the plan, and it bars insurers from denying care based solely on an infertility diagnosis. The Act also introduces required analyses of any utilization-management tools used for fertility benefits over the first five plan years, with subsequent reporting to federal authorities.
The amendments apply to individual and small group market plans and take effect for plan years beginning one year after enactment.
The Five Things You Need to Know
Adds fertility treatment and care as an essential health benefit under ACA (including IVF, preservation, and related services).
Requires parity in cost sharing and treatment limitations between fertility benefits and other medical benefits.
Prohibits denial of fertility coverage based on infertility diagnosis.
Mandates annual utilization-management analyses for fertility benefits during the first five years and a federal reporting requirement.
Applies to individual and small group market plans with an effective date one year after enactment.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Adds fertility treatment and care to essential health benefits
Section 2 amends 1302(b) of the ACA by adding a new subparagraph (K) that defines fertility treatment and care to include preservation of oocytes, sperm, or embryos; artificial insemination; ART (including IVF) and related procedures that handle reproductive material; genetic testing of embryos; fertility medications; gamete donation; and related information and services determined appropriate by the Secretary. The definition references clinical guidelines (e.g., ASRM) and permits expansion of covered items as appropriate.
General requirements for fertility coverage
Subpart II of Part A, Title XXVII is amended to require that fertility treatment and care benefits in individual or small group markets carry financial requirements and treatment limitations that are no more restrictive than the predominant terms for substantially all medical and surgical benefits. There must be no separate cost sharing or separate treatment limitations for fertility benefits that differ from other medical benefits.
Prohibition on denial of care
A health insurance issuer may not deny benefits for fertility treatment and care for an individual solely because the person lacks a diagnosis of infertility. The provision ensures access parity, preventing outright denial based on infertility status.
Utilization management reporting
For each plan year starting one year after enactment, issuers must analyze the application of utilization-management tools to fertility benefits and report to the Secretary and Comptroller General. The report must cover coverage terms, decision factors, evidentiary standards, alignment with clinical guidelines, and any noncompliance findings.
Definitions
Key terms—financial requirement, predominant, and treatment limitation—retain the meanings given in 2726(a)(3), preserving consistency with existing ACA language.
Effective date
The amendments apply to plan years beginning one year after the date of enactment, ensuring a defined, transitional timeline for the new fertility-benefit requirements.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Individuals and couples in the individual or small group markets who need fertility treatments gain access to coverage that addresses a historically unmet financial barrier.
- Fertility clinics, reproductive endocrinologists, and other fertility specialists benefit from clearer coverage rules and parity with other medical benefits, supporting patient access.
- Health insurers and plan sponsors in the individual/small group markets receive a clear framework for applying benefits and reporting, potentially reducing disputes over eligibility and coverage terms.
Who Bears the Cost
- Insurance issuers offering individual or small group market plans may incur additional administration costs to implement parity, reporting, and monitoring requirements.
- Employers sponsoring small-group plans could face higher premiums if utilization increases or if administrative costs rise to meet the new requirements.
- Public payers and the government may incur costs related to oversight and the GA reporting program, including data collection and analysis obligations.
Key Issues
The Core Tension
Balancing broad access to fertility services with the financial and administrative burden on insurers and plan sponsors, while ensuring that utilization management aligns with current clinical guidelines and does not inadvertently increase premiums or reduce patient access.
The bill lowers a potential race to expand fertility benefits across markets by tying coverage parity to existing medical-benefit rules, but it raises questions about premium impact and administrative burden. The utilization-management reporting mandate creates a data-intensive requirement that may strain issuer compliance programs, especially for smaller insurers.
Additionally, the reliance on clinical guidelines to shape covered services could lead to variability in coverage decisions if guidelines evolve differently from payer policies. Finally, the broad definition of “fertility treatment and care” risks broader, more frequent claims, which could affect plan design and budgeting over time.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.